Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database

被引:22
作者
Ito, K. [1 ]
Hutmacher, M. M. [2 ]
Corrigan, B. W. [1 ]
机构
[1] Pfizer Inc, Primary Care Business Unit, Groton, CT 06340 USA
[2] Ann Arbor Pharmacometr Grp, Ann Arbor, MI 48104 USA
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
Bounded outcome data; Disease progression; Alzheimer's disease; ADNI; POPULATION PHARMACODYNAMIC MODEL; ALZHEIMERS-DISEASE; PROGRESSION; VALIDATION;
D O I
10.1007/s10928-012-9271-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An assessment of abilities to function independently in daily life is an important clinical endpoint for all Alzheimer's disease (AD) patients and caregivers. A mathematical model was developed to describe the natural history of change of the Functional Assessment Questionnaire (FAQ) from data obtained in normal elderly, mild cognitive impairment, and mild AD in the AD neuroimaging initiative (ADNI) study. FAQ is a bounded outcome (ranging from 0 to 30), with 0 scored as "no impairment" and 30 as "severely impaired". Since many normal elderly patients had 0 scores and some AD patients had scores of 30 in the ADNI database, a censored approach for handling the boundary data was compared with a standard approach, which ignores the bounded nature of the data. Baseline severity, ApoE4 genotype, age, sex, and imaging biomarkers were tested as covariates. The censored approach greatly improved the predictability of the disease progression in FAQ scores. The basic method for handling boundary data used in this analysis is also applicable to handle boundary observations for numerous other endpoints.
引用
收藏
页码:601 / 618
页数:18
相关论文
共 27 条
  • [1] Likelihood based approaches to handling data below the quantification limit using NONMEM VI
    Ahn, Jae Eun
    Karlsson, Mats O.
    Dunne, Adrian
    Ludden, Thomas M.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2008, 35 (04) : 401 - 421
  • [2] Alzheimer's Association Report 2011 Alzheimer's disease facts and figures
    Thies W.
    Bleiler L.
    [J]. ALZHEIMERS & DEMENTIA, 2011, 7 (02) : 208 - 244
  • [3] Modeling the time-course of Alzheimer dementia.
    Ashford J.W.
    Schmitt F.A.
    [J]. Current Psychiatry Reports, 2001, 3 (1) : 20 - 28
  • [4] Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scores
    Balsis, Steve
    Unger, Alexis A.
    Benge, Jared F.
    Geraci, Lisa
    Doody, Rachelle S.
    [J]. ALZHEIMERS & DEMENTIA, 2012, 8 (04) : 288 - 294
  • [5] Beal SS, 1989, NONMEM User's Guides
  • [6] Repeated measures with zeros
    Berk, KN
    Lachenbruch, PA
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2002, 11 (04) : 303 - 316
  • [7] Brogren Jacob, 2011, ANN M POP APPR GROUP, P21
  • [8] Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
    De Meyer, Geert
    Shapiro, Fred
    Vanderstichele, Hugo
    Vanmechelen, Eugeen
    Engelborghs, Sebastiaan
    De Deyn, Peter Paul
    Coart, Els
    Hansson, Oskar
    Minthon, Lennart
    Zetterberg, Henrik
    Blennow, Kaj
    Shaw, Leslie
    Trojanowski, John Q.
    [J]. ARCHIVES OF NEUROLOGY, 2010, 67 (08) : 949 - 956
  • [9] Population pharmacokinetic modeling: The importance of informative graphics
    Ette, EI
    Ludden, TM
    [J]. PHARMACEUTICAL RESEARCH, 1995, 12 (12) : 1845 - 1855
  • [10] HOLFORD NHG, 1994, EUR J CLIN PHARMACOL, V47, P17